Using MALDI mass spectrometry of serum samples, a prognostic test was created. The test separated MDS patients into groups with better and worse survival, independent of other prognostic factors. The test requires validation on an independent sample set. If validated, the test can provide complementary information for physicians to consider in addition to existing scoring systems to aid in planning treatment for MDS patients.